Haleon plc: Total Voting Rights and Capital
21 March 2024: Haleon plc ("Haleon" or the "Company) announces that the Company has today cancelled 102,272,727 ordinary shares of £0.01 each, repurchased from Pfizer Inc.
As at 21 March 2024 the total number of shares issued by Haleon plc with rights to vote is 9,132,301,104 ordinary shares of £0.01 each. There are no ordinary shares held in Treasury.
The figure of 9,132,301,104 may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The person responsible for arranging the release of this announcement on behalf of Haleon is Amanda Mellor, Company Secretary.
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
